Role of adjuvant metformin therapy on HA1C in type 1 diabetes
Ibrahim Mahmoud Ajwah, Mona Musalm Alatawi, Maram Ibrahim Alanazi, Ruaa Omar Nughays, Samaher Ibrahim Alaauldeen, Lamees Aimen Maghrabi, Arwa Ibrahim Ramel, Hanadi Hezam Althobiati, Fahad Mobarak Alqahtani, Nawaf Abdulkarim Aldhuwayhi, Ebtihal Hassan Bin Selim, Roaid Khan
Abstract
Background
Adequate glycaemic control is a protective strategy against diabetic complication that achieved manly with insulin therapy, studies have shown that type 1 diabetic patients had a reduced insulin sensitivity, on view of this fact, metformin as an insulin sensitizing agent was used in trials as an adjuvant medication to the insulin.
Aims
Current study aimed to summarize the benefit of adjuvant metformin on HA1C in type 1 diabetes on glycaemic control.
Methods
A systematic electronic search was conducted including the Pub Med, Google Scholar, and EBSCO using the following terms in different combinations: metformin, diabetes, HA1c, and C- peptide. Out of two hundred and four articles, only six were included.
Results
Six randomized control trials were identified, aimed to investigate the role of adjuvant metformin on glycaemic control in type 1 diabetes patients. Metformin in dose ranging between 1–2g per day were used for at least three months. Significant HA1c reduction was shown in two out of six trials.
Conclusion
Administering adjunctive metformin therapy in type 1 diabetic patients associated with modest reduction in HA1c, improve insulin resistance as indicated by reduce daily insulin requirement.
Full Text:
Adequate glycaemic control is a protective strategy against diabetic complication that achieved manly with insulin therapy, studies have shown that type 1 diabetic patients had a reduced insulin sensitivity, on view of this fact, metformin as an insulin sensitizing agent was used in trials as an adjuvant medication to the insulin.
Aims
Current study aimed to summarize the benefit of adjuvant metformin on HA1C in type 1 diabetes on glycaemic control.
Methods
A systematic electronic search was conducted including the Pub Med, Google Scholar, and EBSCO using the following terms in different combinations: metformin, diabetes, HA1c, and C- peptide. Out of two hundred and four articles, only six were included.
Results
Six randomized control trials were identified, aimed to investigate the role of adjuvant metformin on glycaemic control in type 1 diabetes patients. Metformin in dose ranging between 1–2g per day were used for at least three months. Significant HA1c reduction was shown in two out of six trials.
Conclusion
Administering adjunctive metformin therapy in type 1 diabetic patients associated with modest reduction in HA1c, improve insulin resistance as indicated by reduce daily insulin requirement.
PDF